Literature DB >> 1562733

Interferon system in primary acute lymphocytic leukemia cells with or without deletions of the alpha-/beta-interferon genes.

D Grandér1, M Heyman, K Bröndum-Nielsen, Y Liu, E Lundgren, S Söderhäll, S Einhorn.   

Abstract

Various aspects of the interferon (IFN) system were studied in malignant cells from 37 unselected patients with acute lymphocytic leukemia (ALL). It was found that leukemic cells from two of 37 patients had a complete loss of alpha- and beta-IFN genes, whereas cells from four of 37 had lost one of the alpha-/beta-IFN alleles. In 25 cases, viable cells were also available for functional studies. Cell clones with loss of one of the alpha-/beta-IFN alleles produced low amounts of IFN after virus induction in vitro. Some clones with an apparently normal set of IFN genes were unable to produce detectable amounts of IFN. All clones studied were found to carry high-affinity alpha-IFN receptors. In clones carrying deletions of IFN genes, the cells were sensitive to IFN in vitro as measured by alpha-IFN-induced enhancement of 2',5'-oligoadenylate synthetase (2',5'-A synthetase). Cells from four patients with an apparently normal set of IFN genes were insensitive to this effect of IFN. We conclude that of the 17 patients in which IFN genes, IFN production, alpha-IFN receptors, and IFN-induced enhancement of 2',5'-A synthetase were studied, nine (53%) showed some abnormality in their IFN system. This finding may add some support to the hypothesis that defects in the IFN system could be a step on the path to malignant transformation in ALL. Moreover, patients whose malignant cells carry IFN gene deletions or other defects in their IFN-producing capacity, but are still sensitive to exogenous IFN, could represent a subgroup of ALL with a greater likelihood of responding to IFN therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1562733

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Progress against cancer.

Authors:  S Broder; J E Karp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 2.  Interferon-alpha in childhood haematological malignancies.

Authors:  R Simkó; K Nagy
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

3.  The Expression of Interferon Gamma (IFN-γ) and Interleukin 6 (IL6) in Patients with Acute Lymphoblastic Leukemia (ALL).

Authors:  Mehdi Allahbakhshian Farsani; Masomeh Kamel; Mahdieh Mehrpouri; Reza Shiri Heris; Mohsen Hamidpour; Sina Salari; Mohamad Hosien Mohamadi
Journal:  Pathol Oncol Res       Date:  2018-11-15       Impact factor: 3.201

4.  Detection of allelic loss within the beta 1-interferon gene in childhood acute lymphoblastic leukemia using differential PCR.

Authors:  C A Schmidt; A Neubauer; K H Seeger; C F Rochlitz; T Binder; H Oettle; G Henze; E T Liu; D Huhn; W Siegert
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

Review 5.  Human natural interferon-alpha producing cells.

Authors:  P Fitzgerald-Bocarsly
Journal:  Pharmacol Ther       Date:  1993-10       Impact factor: 12.310

6.  HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes in antigen presenting cells.

Authors:  Sami Kukkonen; Maria Del Pilar Martinez-Viedma; Nayoung Kim; Mariana Manrique; Anna Aldovini
Journal:  Retrovirology       Date:  2014-04-17       Impact factor: 4.602

Review 7.  Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.

Authors:  Ruan F V Medrano; Aline Hunger; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Oncotarget       Date:  2017-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.